Log in
Enquire now
‌

US Patent 6894071 Medical compositions for intravesical treatment of bladder cancer

Patent 6894071 was granted and assigned to Spectrum Pharmaceuticals on May, 2005 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
0
Current Assignee
Spectrum Pharmaceuticals
Spectrum Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
68940710
Patent Inventor Names
Ernie Pfadenhauer0
Bastiaan Nuijen0
Jos H. Beijnen0
Date of Patent
May 17, 2005
0
Patent Application Number
102857830
Date Filed
November 1, 2002
0
Patent Primary Examiner
‌
John Pak
0
Patent abstract

Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 6894071 Medical compositions for intravesical treatment of bladder cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.